Join Leyla Gulen on this edition of Global Market Bulletin TV as she speaks to Cryoport’s (NASDAQ: CYRX) Chief Scientific Officer Mark W. Sawicki, Ph.D., and Vice President of Corporate Development Thomas J. Heinzen about the latest progress that has made Cryoport a premier provider in temperature-controlled supply chain services for life sciences organizations worldwide!
Mr. Sawicki and Mr. Heinzen beamed with pride as they announced the company’s remarkable 2022 results, which included a staggering total of $237 million in revenue with commercial income up by 27%. Additionally, Cryoport is currently aiding an unprecented 654 global clinical trials and 10 commercial therapies!
The Cryoport executive team recently celebrated the inception of their strategic alliance with Syneos Health, an integrated biopharmaceutical solutions provider designed to expedite customer success.
About Cryoport Chief Scientific Officer Mark W. Sawicki, Ph.D.
With 15 years of experience in both business development and sales management, Mark Sawicki has been a critical factor to the success of numerous pharmaceutical and biotechnology corporations. Most recently as Chief Business Officer at AAIPharma Services Corporation/Cambridge Major Laboratories Inc., Mark achieved immense results that have catapulted it into further prosperity. His impressive business development roles at CMC Biologics and Albany Molecular Research Inc. (AMRI) demonstrate his resolve to boost revenue well beyond the industry standard.
After receiving his Bachelor’s degree in Biochemistry from the State University of New York at Buffalo, Dr. Sawicki went on to pursue a Ph.D., graduating magna cum laude from SUNY-Buffalo School of Medicine and Biomedical Sciences as well as receiving graduate training by Hauptman Woodard Medical Research Institute. His illustrious academic career clearly demonstrates his relentless pursuit of excellence and unwavering commitment to lifelong learning.
Having a distinguished scientific career that has spanned over the last ten years, he is renowned for his outstanding papers on Drug Discovery which have especially highlighted Immunology and Oncology research. Consequently, this highly coveted scientist is in global demand today!
About Cryoport Vice President of Corporate Development Thomas J. Heinzen
With an extensive 20+ year background in investment banking and equity trading, Thomas Heinzen has become a major asset at Cryoport. Prior to joining the company in 2015, he was both Head of Trading at Protective Group Securities and Senior Vice President at Emergent Financial Group – showcasing his remarkable skillset. Additionally, Thomas is currently Chairman for Spire Credit Union while also possessing Series 4, 7, 55 63 and 65 security licenses with a Bachelor’s Degree in Finance from University St.Thomas – further demonstrating his capability as an executive leader in finance.
For life sciences organizations needing temperature-controlled delivery solutions, Cryoport is the premier provider. With their revolutionary product, the Cryoport Express® liquid nitrogen dry vapor shipper, and additional offerings such as C3™ 2-8°C solution and Smartpak II® condition monitoring system powered by pioneering geo-sensing technology – Cryoport offers a comprehensive suite of services to meet your needs.
With top-notch cold chain knowledge and 24/7 customer service, you can rely on their comprehensive supply chain partner package – enabled by the unique logistics management platform: Cryoportal®.
Learn more about Cryoport on their official website.